TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-21,045.36%
Return on Equity-137.69%
Return on Assets-83.60%
Miscellaneous
EmployeesN/A
Outstanding Shares208,970,000
Market Cap$354.65 million
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) issued its quarterly earnings data on Tuesday, August, 7th. The medical instruments supplier reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06). The medical instruments supplier had revenue of $6.39 million for the quarter, compared to analyst estimates of $6.20 million. TransEnterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%. View TransEnterix's Earnings History.
When is TransEnterix's next earnings date?
What price target have analysts set for TRXC?
3 brokers have issued 1 year target prices for TransEnterix's stock. Their predictions range from $4.00 to $5.50. On average, they anticipate TransEnterix's share price to reach $4.75 in the next year. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for TransEnterix.
What is the consensus analysts' recommendation for TransEnterix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TransEnterix.
Are investors shorting TransEnterix?
TransEnterix saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 33,008,055 shares, an increase of 5.2% from the July 13th total of 31,370,262 shares. Based on an average daily trading volume, of 6,617,300 shares, the days-to-cover ratio is presently 5.0 days. Currently, 21.3% of the company's shares are short sold. View TransEnterix's Current Options Chain.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Advanced Medical Solutions (AMS), CRH Medical (CRH), CRH Medical (CRHM), Tristel (TSTL), TSO3 (TOS), Clover (CLV), Bovie Medical (BVX), InfuSystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), IsoRay (ISR), Akers Biosciences (AKR), Daxor (DXR), Omega Diagnostics Group (ODX) and Relevium Technologies (RLV).
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Has TransEnterix been receiving favorable news coverage?
Headlines about TRXC stock have trended somewhat positive on Saturday, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. TransEnterix earned a news and rumor sentiment score of 0.01 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 48.56 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for TransEnterix.
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.89%), Global X Management Co LLC (1.23%), Eagle Asset Management Inc. (0.39%), Bank of New York Mellon Corp (0.25%), Tibra Equities Europe Ltd (0.19%) and Schwab Charles Investment Management Inc. (0.16%). Company insiders that own TransEnterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope and Willam N Kelley. View Institutional Ownership Trends for TransEnterix.
Which major investors are selling TransEnterix stock?
TRXC stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE. Company insiders that have sold TransEnterix company stock in the last year include Anthony C J Fernando, Joseph P Slattery and Todd Pope. View Insider Buying and Selling for TransEnterix.
Which major investors are buying TransEnterix stock?
TRXC stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Global X Management Co LLC, Eagle Asset Management Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., EAM Global Investors LLC, EAM Investors LLC and Rhumbline Advisers. Company insiders that have bought TransEnterix stock in the last two years include Andrea Biffi, Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $4.57.
How big of a company is TransEnterix?
TransEnterix has a market capitalization of $354.65 million.
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
